8-K: Corvus Pharma Raises $188.3M in Public Stock Offering

Corvus Pharmaceuticals, Inc. successfully completed an underwritten public offering of 9,085,778 shares of common stock, including the full exercise of the underwriters' option, generating approximately $188.3 million in net proceeds.

Summary

• Corvus Pharmaceuticals, Inc. entered into an underwriting agreement on January 21, 2026, for a public offering of its common stock.
• The company initially offered 7,900,677 shares of common stock at a public offering price of $22.15 per share.
• Underwriters, including Jefferies LLC and Goldman Sachs & Co. LLC, purchased these shares at $20.821 per share.
• An option was granted to underwriters for an additional 1,185,101 shares, which was fully exercised on January 22, 2026.
• The total number of shares sold in the offering, including option shares, is 9,085,778.
• The offering is expected to close on January 23, 2026, subject to customary closing conditions.
• Net proceeds to the company, after deducting underwriting discounts, commissions, and estimated offering expenses, are approximately $188.3 million.
• Proceeds are intended for working capital, general corporate purposes, capital expenditures, and research and development, specifically for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials, as well as sales, marketing, and administrative expenses.
• Directors and officers of the company are subject to a 45-day lock-up period, restricting the sale or transfer of common stock or related securities.

Sentiment

Score: 7

Explanation: The successful completion of a significant capital raise, including the full exercise of the overallotment option, is a strong positive for a clinical-stage biotechnology company, providing essential funding for its R&D pipeline and operations. While dilution is a factor, the ability to secure substantial financing for strategic initiatives generally outweighs this for growth-focused biotech firms.

Positives

• Successfully raised approximately $188.3 million in net proceeds, significantly bolstering the company's financial position.
• The capital infusion provides funding for critical research and development initiatives, including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.
• The full exercise of the underwriters' option indicates strong market demand and confidence in the offering.
• Funds will also support general corporate purposes, capital expenditures, and sales and marketing efforts, enabling broader operational capabilities.

Negatives

• The issuance of 9,085,778 new shares will result in significant dilution for existing shareholders.
• Underwriters purchased shares at a discount ($20.821 per share) compared to the public offering price ($22.15 per share), representing a cost to the company.

Risks

• Actual results could differ materially from forward-looking statements due to uncertainties related to market conditions and the completion of the public offering on anticipated terms or at all.
• The company's forward-looking statements involve assumptions that, if incorrect, could cause results to differ materially.
• Risks concerning the company's business are described in additional detail in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and other SEC filings.
• The company is under no obligation to update or alter its forward-looking statements.

Future Outlook

The company intends to use the net proceeds from the offering to fund working capital, general corporate purposes, capital expenditures, and research and development, specifically for its Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials, as well as sales and marketing and administrative expenses.

Management Comments

• The company acknowledges that the Underwriters and counsel will rely upon the accuracy and truthfulness of the representations and consents to such reliance.
• The company has a reasonable basis for making each of the representations set forth in the underwriting agreement.

Industry Context

This public offering is a common strategy for biotechnology companies like Corvus Pharmaceuticals to raise substantial capital. Such funding is crucial for financing extensive and costly research and development activities, particularly for advancing drug candidates through various phases of clinical trials, which is typical in the biopharmaceutical industry.

Comparison to Industry Standards

• The structure of this underwritten public offering, including the grant and full exercise of an overallotment option, is standard practice for capital raises in the biotechnology sector.
• The use of proceeds for R&D, particularly for advancing clinical trials (Phase 3 T cell lymphoma, Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma), aligns with typical funding priorities for clinical-stage biopharmaceutical companies.
• The 45-day lock-up period for directors and officers is a customary measure to ensure market stability post-offering, comparable to similar transactions by peer companies in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new shares but benefit from the company's strengthened financial position and ability to fund future growth initiatives, particularly R&D.
• Employees: Continued employment and R&D activities are supported by the capital raise, potentially leading to stability and future opportunities.
• Customers/Patients: The funding directly supports the advancement of clinical trials for potential new therapies, which could ultimately benefit future patients.
• Creditors: A stronger cash position may improve the company's creditworthiness and ability to meet financial obligations.

Next Steps

• The offering is expected to close on January 23, 2026, subject to customary closing conditions.
• The company will apply the net proceeds to working capital, general corporate purposes, capital expenditures, and research and development, including advancing its Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.
• The company will continue to comply with Securities Act and Exchange Act requirements to permit the completion of the distribution of the offered shares.

Key Dates

Keywords

Corvus Pharmaceuticals, Public Offering, Common Stock, Capital Raise, Underwriting Agreement, CRVS, Nasdaq, Biotechnology, Clinical Trials, T cell lymphoma, Atopic Dermatitis, Hidradenitis Suppurativa, Asthma, R&D Funding